In 2012 he obtained a doctor honoris causa from the Charles University of Prague. Advisory Board: Boehringer Ingelheim; Keryx; Reata Consultant: AMAG; Baxter; Boehringer Ingelheim; Reata Development of Educational Materials: Mitsubishi Grant/Research Support: Genzyme* Speaker: Abbott; Amgen; Astellas; AstraZeneca; Bristol- Myers Squibb; Fresenius Medical Care; Genzyme; Merck Sharp & Dohme; Mitsubishi; Roche *monies paid to institution Alan Cass, MBBS, FRACP, PhD, is Director of the Menzies School of Health Research in Darwin, Australia and previously served as Senior Director, Renal and Metabolic Division, The George Institute for Global Health in Sydney, Australia. Dr Cass completed his nephrology training and PhD studies at the University of Sydney where he investigated the social determinants of ESRD. His current research encompasses the use of rigorous quantitative and qualitative methods to foster the development, implementation and evaluation of strate- gies to address the growing burden of CKD. He also conducts primary care intervention research aiming to reduce barriers to necessary care for Indigenous Australians and enhance access to renal services in remote areas, thereby improving their health outcomes. Dr Cass is President-Elect for the Australian and New Zealand Society of Nephrology (ANZSN), a member of the Executive of the Australasian Kidney Trials Network and International Society of Nephrol- http://www.kidney-international.org biographic and disclosure information & 2013 KDIGO ogy (ISN) CKD Policy Task Force. An author of over 150 publications, he recently received the 2012 NSW Aboriginal Health Award for Closing the Gap through Excellence in Chronic Care, and the 2013 T J Neale Award for Outstanding Contribution to Nephrological Science from ANZSN. 